[ A21-86] Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2021
Project no.:
A21-86
Commission:
Commission awarded on 23.06.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment of adult patients with stage IB to IIIA non-small cell lung cancer (NSCLC) with exon 19 deletion or exon 21 substitution mutation (L858R) of the epidermal growth factor receptor (EGFR) after complete tumour resection
- Without prior adjuvant platinum-based chemotherapy: added benefit not proven.
- Patients after prior adjuvant platinum-based chemotherapy or for whom this therapy it is not suitable: hint of considerable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-45 | Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-20 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-14 | Osimertinib - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-77 | Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-72 | Osimertinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |